Having completed chemotherapy (intravenous) for breast cancer (any stage) less than 12 months prior to inclusion
Having a perceived cognitive complaint that appeared during or after (\< 3 months) chemotherapy treatments (no restriction on the care protocol used) and confirmed by a FACT-Cog score compatible with a subjective cognitive disorder (score \< 117 for patients aged 18 to 49; score \< 113 for patients aged 50 to 69; score \<105 for patients aged 70 and over)
Patient eligible for photobiomodulation sessions
Patient with sufficient command of the French language to complete the study questionnaries
Patient having given written consent to participate in the trial
Socially insured patient
Patient willing to comply with all study procedures and duration
You may not be if
Known cognitive disorders prior to chemotherapy treatment
Patients with psychiatric or psychobehavioral disorders incompatible with photobiomodulation sessions
Patients who, in the 12 months prior to inclusion or at the time of inclusion, have already received photobiomodulation treatment involving "whole body" therapy (photobiomodulation in a phototherapy booth).
Patient having previously received photobiomodulation with cortical stimulation (panel or helmet) with no time limit.
Patient taking or having received capecitabine
Patients taking part in a protocol involving a drug likely to affect cognitive performance (on the investigator's advice).
Patients suffering from claustrophobia
Patient unable to read and/or unable to complete a questionnaire, in the opinion of the investigator
